Consistently, inhibition of the major DNA damage response-associated PARP, PARP1, is known to be particularly lethal to tumor cells with homologous recombination deficiencies, especially those based on defects in the BRCA1/2-dependent pathway. The gene discussed is PARP1; the disease is neoplasm.